Latent Tuberculosis in the light of the New International Guidelines

Katerina Manika

3/2015 vol. 28

Stats

Get citation

EDITORIAL

Latent Tuberculosis in the light of the New International Guidelines

Katerina Manika ¹

More details

Hide details

Assistant Professor in Pulmonary Medicine, Respiratory Infections Unit, Pulmonary Medicine Clinic, Aristotle University of Thessaloniki

Corresponding author

Katerina Manika

Respiratory Infections Unit Pulmonary Medicine Clinic Aristotle University of Thessaloniki G. Papanicolaou Hospital, 57010 Exohi, Thessaloniki, Greece

Pneumon 2015;28(3):218-220

Article (PDF)

References (15)

REFERENCES (15)

World health Organisation. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01.

Google Scholar

Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-35.

Google Scholar

Achkar JM, Jenny-Avital ER. Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response. J Infect Dis 2011;204:S1179–86.

Google Scholar

Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 2014;179:216-25.

Google Scholar

Marais BJ, Schaaf S, Menzies D. Prevention of TB in areas with high inceidence. Eur Respir Monogr 2012;58:84-94.

Google Scholar

Pai M, Kunimoto D, Jamieson F, Menzies D. Chapter 4: Diagnosis of latent tuberculosis infection. In: Canadian Tuberculosis Standards, 7th edition., Can Respir J 2013;20:s23A-34A.

Google Scholar

U.S. Department of Health and Human Services. Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. 2013.

Google Scholar

ATS/CDC. Targeted tuberculin testing and treatment of latent TB infection. Am J Respir Crit Care Med 2000;161:S221-47.

Google Scholar

Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-49.

Google Scholar

10.

Bothamley GH, Ditiu L, Migliori GB, Lange C, TBNET contributors. Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey Eur Respir J 2008;32:1023–30.

Google Scholar

11.

Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative Performance of Tuberculin Skin Test, QuantiFERON-TB-Gold In Tube Assay, and T-Spot.TB Test in Contact Investigations for Tuberculosis. CHEST 2009;135:1010–18.

Google Scholar

12.

Comstock GW. How much isoniazid is needed for prevention of tuberculosis among imunocompetent adults? Int J Tuberc Lung Dis 1999;10:847-50.

Google Scholar

13.

Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV persons. Cochrane Daabase Syst Rev 2000;(2):CD001363.

Google Scholar

14.

Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of Latent Tuberculosis Infection. A Network Metaanalysis. Ann Intern Med 2014;161:419-28.

Google Scholar

15.

Menzies D, Alvarez GG, Khan Kamran. Chapter 6: Treatment of latent tuberculosis infection. In: Canadian Tuberculosis Standards, 7th edition. Can Respir J 2013;20:s44A-53A.

Google Scholar

Submit your paper

Instructions to Authors

Issues

Indexes

eISSN:	1791-4914
ISSN:	1105-848X